

Resolution



of the Federal Joint Committee (G-BA) on an amendment of the Pharmaceuticals Directive (AM-RL):

Annex XII – Amendment of information on the period of validity of a resolution on the benefit assessment of medicinal products with new active ingredients according to Section 35a SGB V Nusinersen

From 16. May 2019

At its meeting on 16. May 2019, the Federal Joint Committee (G-BA) decided to amend the Directive on the Prescription of Medicinal Products in SHI-accredited Medical Care (Pharmaceuticals Directive) in the version dated 18 December 2008/22 January 2009 (BAnz. No. 49a of 31 March 2009), as last amended on 1. Monat JJJJ (BAnz. AT TT.MM.JJJJ BX), as follows:

- I. In Annex XII, the provision under II.2. concerning the period of validity of the resolution on the benefit assessment Nusinersen of 21 December 2017 shall be amended as follows:**

The entry “1 January 2020”, which entered into force by the resolution of 21 December 2017, shall be replaced by the entry “1 July 2024”.

- II. The resolution will enter into force on the day of its publication on the Internet on the websites of the Federal Joint Committee on 16. May 2019.**

The justification to this resolution will be published on the website of the Federal Joint Committee at www.g-ba.de.

Berlin, 16. May 2019

Federal Joint Committee
in accordance with Section 91 SGB V
Chair

Prof Hecken